文献速递免疫规划慢病防控与筛查

既往感染SARS-CoV-2的肺移植受者接种mRNA新冠疫苗可诱导持久的SARS-CoV-2特异性抗体和T细胞

mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
PubMed 文献 · Vaccine · 2024-09-02

本研究纳入既往自然感染SARS-CoV-2的肺移植受者,在其感染后中位184天时以28天间隔接种两剂mRNA-1273新冠疫苗。接种后S特异性抗体显著升高,6个月时抗体和病毒特异性T细胞反应仍显著高于接种前,中和抗体对Omicron BA.5保留交叉反应但水平较低。

要点

  • 既往感染的肺移植受者接种mRNA-1273后S特异性抗体显著升高,第二剂后进一步升高。
  • 首剂后产生IFN-γ的T细胞增加,第二剂后未检测到额外增强。
  • 接种后6个月抗体和病毒特异性T细胞反应仍显著高于接种前水平。

核心结论

  • mRNA新冠疫苗对既往有免疫力的肺移植受者具有免疫原性,抗体和T细胞反应在接种后可持续至6个月。

研究设计与样本

  • 研究纳入既往自然感染SARS-CoV-2的肺移植受者,在感染后中位184天时以28天间隔接种两剂mRNA-1273新冠疫苗。
  • 于接种前、首剂后28天、第二剂后28天及第二剂后6个月采集血样。
  • 检测S和N特异性抗体、对祖先株和Omicron BA.5的中和活性,并用IFN-γ ELISpot、IGRA和流式细胞术评估S特异性T细胞反应。

主要发现

  • 多数既往感染的肺移植受者在基线时已可检测到S特异性抗体和T细胞。
  • 首剂接种后S特异性抗体水平显著升高,第二剂后进一步升高。
  • 研究期间N特异性抗体下降,提示未发生新的突破性感染。
  • 首剂后产生IFN-γ的T细胞增加,第二剂后未检测到额外增强。
  • 接种后6个月抗体水平和病毒特异性T细胞反应仍显著高于接种前水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung transplant recipients (LTRs) are particularly at risk of developing severe coronavirus disease-2019 (COVID-19), but are also difficult to protect by vaccination due to their immunocompromised state. Here, we investigated the immunogenicity of mRNA-based COVID-19 vaccines in LTRs who had a prior natural SARS-CoV-2 infection. At a median of 184 days after SARS-CoV-2 infection, LTRs were vaccinated twice with the mRNA-1273 COVID-19 vaccine, with a 28-day interval. Blood samples were obtained pre-vaccination, 28 days after the first dose, and 28 days and 6 months after the second dose. Spike (S-) and nucleocapsid (N-) specific antibodies were measured, as well as neutralization of the ancestral and Omicron BA.5 variant. S-specific T cell responses were evaluated using IFN-γ ELISpot,IGRA, and activation markers by flow cytometry. Phenotyping of T cells was performed by using high-resolution spectral flow cytometry. Most LTRs with prior infection had detectable S-specific antibodies and T cells at baseline. After the first vaccination, S-specific antibody levels increased significantly; an additional increase was observed after the second vaccination. N-specific antibodies decreased during the study period, indicative of the fact that no further breakthrough infections occurred. An increase in IFN-γ producing T cells was observed after the first vaccination, but no additional boost could be detected after the second vaccination. Antibody levels and virus-specific T cell responses remained significantly higher compared to pre-vaccination levels at 6 months post-vaccination, indicating an additive and durable effect of vaccination after infection in LTRs. Neutralizing antibodies were detected against the ancestral strain and retained cross-reactivity with Omicron BA.5, albeit at lower levels. Moreover, the quantity and phenotype of SARS-CoV-2 spike-specific T cells were similar in LTRs compared to controls with hybrid immunity. In conclusion, mRNA-based COVID-19 vaccines are immunogenic in LTRs with prior immunity, and antibody and T cell responses are durable up to 6 months post-vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu S, van Dijk LLA, den Hartog Y, et al. mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells. Vaccine. 2024. PMID: 39226789. doi:10.1016/j.vaccine.2024.126250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。